search
Back to results

Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System (TriStar)

Primary Purpose

Tricuspid Regurgitation

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Transcatheter Annuloplasty
Sponsored by
Shanghai Huihe Medical Technology Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tricuspid Regurgitation

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥60, male or female;
  2. patients with severe or above secondary tricuspid regurgitation (TR≥4+) (secondary tricuspid regurgitation: tricuspid regurgitation caused by right atrial lesions, right ventricular cardiomyopathy, right ventricular myocardial infarction, left ventricular valvular disease, congenital heart disease and other diseases);
  3. A multidisciplinary cardiac team (at least 2 doctors) consisting of cardiovascular physicians, cardiovascular surgeons, radiologists, anesthesiologists, etc., considered the subject to be at high risk for surgery and expected to benefit from tricuspid valve repair;
  4. Left ventricular ejection fraction LVEF≥40%;
  5. The subject voluntarily participates in the clinical trial and agrees or his/her guardian agrees to sign the informed consent.
  6. Tricuspid regurgitation symptoms, such as chest tightness, asthma, shortness of breath, lower limb edema, ascites;
  7. NYHA grade 2 to 4;
  8. Patients who received tricuspid valve optimal drug therapy for ≥ 30 days were in stable condition;
  9. In the case of the following diseases: mitral regurgitation, atrial fibrillation, coronary disease and heart failure, drug treatment should be ≥ 30 days or ≥ 30 days after instrumental treatment and the patient's condition is stable.

Exclusion Criteria:

  1. patients with primary tricuspid regurgitation;
  2. Patients with systolic pulmonary artery pressure ≥55 mmHg;
  3. Patients with tricuspid valve or annuloplasty or tricuspid related procedure;
  4. Patients with posterior tricuspid annulus calcification;
  5. Evidence of mass, thrombosis or vegetations in the heart, jugular vein and superior vena cava;
  6. patients with moderate or higher aortic stenosis, mitral stenosis, aortic regurgitation or mitral regurgitation;
  7. patients with severely uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg);
  8. Percutaneous coronary intervention within 1 month;
  9. myocardial infarction or known unstable angina within 1 month;
  10. Cerebrovascular accident within the past 3 months;
  11. patients with active endocarditis or active rheumatic heart disease;
  12. Patients with coagulation dysfunction, hypercoagulability or anemia (hemoglobin < 90 g/L);
  13. patients with acute infection or other severe infection;
  14. Patients with active peptic ulcer or active gastrointestinal bleeding;
  15. severe end-stage diseases (such as malignant tumor, severe lung disease, liver disease, renal failure) with a life expectancy of less than one year;
  16. Patients with known allergies or contraindications to the raw materials or drugs (such as antiplatelet drugs and anticoagulants) of the test products;
  17. Persons addicted to alcohol, drugs or drugs;
  18. Patients with cognitive impairment;
  19. patients with histories of epilepsy or mental illness;
  20. Participate in any other clinical trial (other than a registry study) within 30 days prior to signing the informed consent;
  21. have a previous implantation of a pacemaker or defibrillator, or plan to implant a pacemaker or defibrillator;
  22. Tricuspid stenosis;
  23. Ebstain syndrome;
  24. The anatomy of tricuspid annulus could not be assessed by TEE and TTE;
  25. Hemodynamic instability;
  26. chronic dialysis patients;
  27. women who are pregnant during pregnancy, breast-feeding or during the clinical study;
  28. Other conditions that the investigator considers inappropriate for participation in the clinical trial.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    K-clipTM transcatheter annuloplasty system

    Arm Description

    Outcomes

    Primary Outcome Measures

    All-cause mortality
    Change of Tricuspid Regurgitation Grade
    Change of Tricuspid Regurgitation Grade assessed by corelab than baseline

    Secondary Outcome Measures

    The success rate of post operation 12 months
    Success rate of device implantation
    Change in echocardiographic parameters
    Change in echocardiographic parameters:Tricuspid annulus A-P diameter(mm)、 Tricuspid annulus perimeter(mm)、Tricuspid annulus area(cm2)、Vena contracta width(mm)、EROA(cm2)、Regurgitation volume(ml)、IVC(mm)。
    Change of Tricuspid Regurgitation Grade
    NYHA
    6 minutes walk distance
    Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Full Information

    First Posted
    December 27, 2021
    Last Updated
    April 20, 2022
    Sponsor
    Shanghai Huihe Medical Technology Co., Ltd
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05173233
    Brief Title
    Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System
    Acronym
    TriStar
    Official Title
    Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    May 15, 2022 (Anticipated)
    Primary Completion Date
    May 15, 2023 (Anticipated)
    Study Completion Date
    May 15, 2027 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Shanghai Huihe Medical Technology Co., Ltd

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    The present clinical trial is performed to evaluate the effectiveness and safety of transcatheter tricuspid annuloplasty system manufactured by Shanghai Huihe Healthcare technology Co.,Ltd. for the treatment of subjects with severe or worse tricuspid regurgitation.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Tricuspid Regurgitation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    67 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    K-clipTM transcatheter annuloplasty system
    Arm Type
    Experimental
    Intervention Type
    Device
    Intervention Name(s)
    Transcatheter Annuloplasty
    Intervention Description
    Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
    Primary Outcome Measure Information:
    Title
    All-cause mortality
    Time Frame
    1-year after operation
    Title
    Change of Tricuspid Regurgitation Grade
    Description
    Change of Tricuspid Regurgitation Grade assessed by corelab than baseline
    Time Frame
    1-year after operation
    Secondary Outcome Measure Information:
    Title
    The success rate of post operation 12 months
    Time Frame
    2 years, 3years, 4 years, 5 years
    Title
    Success rate of device implantation
    Time Frame
    intra-procedure
    Title
    Change in echocardiographic parameters
    Description
    Change in echocardiographic parameters:Tricuspid annulus A-P diameter(mm)、 Tricuspid annulus perimeter(mm)、Tricuspid annulus area(cm2)、Vena contracta width(mm)、EROA(cm2)、Regurgitation volume(ml)、IVC(mm)。
    Time Frame
    1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years
    Title
    Change of Tricuspid Regurgitation Grade
    Time Frame
    1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years
    Title
    NYHA
    Time Frame
    1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years
    Title
    6 minutes walk distance
    Time Frame
    1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years
    Title
    Kansas City Cardiomyopathy Questionnaire (KCCQ)
    Time Frame
    1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age ≥60, male or female; patients with severe or above secondary tricuspid regurgitation (TR≥4+) (secondary tricuspid regurgitation: tricuspid regurgitation caused by right atrial lesions, right ventricular cardiomyopathy, right ventricular myocardial infarction, left ventricular valvular disease, congenital heart disease and other diseases); A multidisciplinary cardiac team (at least 2 doctors) consisting of cardiovascular physicians, cardiovascular surgeons, radiologists, anesthesiologists, etc., considered the subject to be at high risk for surgery and expected to benefit from tricuspid valve repair; Left ventricular ejection fraction LVEF≥40%; The subject voluntarily participates in the clinical trial and agrees or his/her guardian agrees to sign the informed consent. Tricuspid regurgitation symptoms, such as chest tightness, asthma, shortness of breath, lower limb edema, ascites; NYHA grade 2 to 4; Patients who received tricuspid valve optimal drug therapy for ≥ 30 days were in stable condition; In the case of the following diseases: mitral regurgitation, atrial fibrillation, coronary disease and heart failure, drug treatment should be ≥ 30 days or ≥ 30 days after instrumental treatment and the patient's condition is stable. Exclusion Criteria: patients with primary tricuspid regurgitation; Patients with systolic pulmonary artery pressure ≥55 mmHg; Patients with tricuspid valve or annuloplasty or tricuspid related procedure; Patients with posterior tricuspid annulus calcification; Evidence of mass, thrombosis or vegetations in the heart, jugular vein and superior vena cava; patients with moderate or higher aortic stenosis, mitral stenosis, aortic regurgitation or mitral regurgitation; patients with severely uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg); Percutaneous coronary intervention within 1 month; myocardial infarction or known unstable angina within 1 month; Cerebrovascular accident within the past 3 months; patients with active endocarditis or active rheumatic heart disease; Patients with coagulation dysfunction, hypercoagulability or anemia (hemoglobin < 90 g/L); patients with acute infection or other severe infection; Patients with active peptic ulcer or active gastrointestinal bleeding; severe end-stage diseases (such as malignant tumor, severe lung disease, liver disease, renal failure) with a life expectancy of less than one year; Patients with known allergies or contraindications to the raw materials or drugs (such as antiplatelet drugs and anticoagulants) of the test products; Persons addicted to alcohol, drugs or drugs; Patients with cognitive impairment; patients with histories of epilepsy or mental illness; Participate in any other clinical trial (other than a registry study) within 30 days prior to signing the informed consent; have a previous implantation of a pacemaker or defibrillator, or plan to implant a pacemaker or defibrillator; Tricuspid stenosis; Ebstain syndrome; The anatomy of tricuspid annulus could not be assessed by TEE and TTE; Hemodynamic instability; chronic dialysis patients; women who are pregnant during pregnancy, breast-feeding or during the clinical study; Other conditions that the investigator considers inappropriate for participation in the clinical trial.

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes

    Learn more about this trial

    Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System

    We'll reach out to this number within 24 hrs